Clinical Trial Update: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating MRG002 for HER2-positive unresectable locally advanced or metastatic breast cancer spanning Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MRG002

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2, Phase 3 | Status: UNKNOWN